Ambrx Inks Three-Target Deal With Wyeth To Develop Antibody-Toxin Conjugates
This article was originally published in The Pink Sheet Daily
Executive Summary
First license deal for Ambrx's EuCode technology offers potential for "silver bullet" therapeutics that localize pharmacologic activity.